🟢 Tvardi Therapeutics is trading 6.9% up in pre-market after Chardan initiated coverage with a Buy

Tvardi Therapeutics is trading at $1.06, up 6.85%, after Chardan initiated coverage with a Buy rating and an $8.00 price target.

• Chardan’s October 20 coverage announcement was linked to a premarket rise.
• Management presented at Chardan’s healthcare conference on October 20, but no new company announcement for October 21 was identified.
• The biotech sector is also strong in pre-market, with XBI up 3.64%; that may add support, though Chardan’s initiation is the specific catalyst.